Neurogastroenterology & Motility · 2011 · 18 citations · 40 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyGastrointestinal PharmacotherapyPharmacodynamicsEsophageal DiseasesGastroesophageal Reflux DiseaseGastrointestinal MotilityGastrointestinal PathophysiologyGastrointestinal PharmacologyCholinergic Prokinetic AgentsEsophageal Food Bolus ObstructionMosapride TherapyMotility PharmacologyPharmacologic Therapy For GerdSerotonin 5-Ht4 Receptor AgonistsSubjects
BACKGROUND: Secondary peristalsis is important for the clearance of refluxate or retained food bolus from the esophagus. Mosapride is a prokinetic agent that enhances GI motility by stimulating 5-hydroxytrypatamine(4) (5-HT(4) ) receptors, but its effects on secondary peristalsis are yet unclear in humans. We aimed to investigate the effect of a 5-HT(4) agonist mosapride on esophageal distension-induced secondary peristalsis in normal subjects. METHODS: After a baseline recording esophageal motility, secondary peristalsis was generated by slow and rapid mid-esophageal injections of air in 15 healthy subjects. Two separate sessions with 40mg oral mosapride or placebo were randomly performed to test their effects on esophageal secondary peristalsis. KEY RESULTS: Mosapride decreased the threshold volume for triggering secondary peristalsis during rapid air distension (4.5±0.3 vs 5.3±0.4mL; P=0.04) but not slow air distension (14.3±1.2 vs 13.3±1.3mL; P=0.41). Secondary peristalsis was triggered more frequently in response to rapid air distension after application of mosapride [100% (90-100%) vs 90% (80-100%); P=0.02]. Mosapride significantly increased pressure wave amplitudes of secondary peristalsis during slow (135.4±13.8 vs 105.0±12.9mmHg; P=0.001) and rapid air distensions (124.0±11.6 vs 95.9±14.0mmHg; P=0.002). CONCLUSIONS & INFERENCES: Mosapride enhances sensitivity to distension-induced secondary peristalsis and facilitates secondary peristaltic contractility. These data provide an evidence for modulation of esophageal secondary peristalsis by the 5-HT(4) agonist mosapride, as well support for its clinical utility.
40
Ali Kermanizadeh, Sandra Vranic, Sonja Boland et al. · BMC Nephrology · 2013 · 186 citations · Full text